PPP023 - New Immunotherapy Agents for Cancer with Jim Siderov

Jim Siderov is the senior Oncology Pharmacist at Austin Health. He is also an Australian Advanced Practice Pharmacist and is US Board Certified in Oncology Pharmacy. 

We speak to Jim about: 

• Checkpoint inhibitors: their mechanism and role in oncology 

• Autoimmune toxicities and how they are managed clinically 

• Emerging evidence and future potential uses for these agents 

Further information: 

Nivolumab for melanoma, non-small cell lung cancer Aust Prescr 2016;39:138-40 

Pembrolizumab for metastatic melanoma Aust Prescr 2015;38:180-82 

Bourke JM, O'Sullivan M, Khattak MA. Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors). Med J Aust 2016; 205 (9): 418-424